Also known as: Mimosa #26 · Purple Mimosa (separate cut)

Mimosa

A citrus-forward Symbiotic Genetics hybrid that became a 2018-era flagship and a template for the modern 'orange' flavor lane.

Sourced and fact-checked
6 cited sources
Published 1 month ago
How this page was made
↯ The honest take

Mimosa is a real, well-documented Symbiotic Genetics cross that genuinely tastes like citrus and pours strong on THC tests. Beyond that, almost everything you read about it — 'energizing daytime sativa,' 'great for anxiety,' specific terpene percentages — is marketing or vibes. There is no strain-specific clinical research on Mimosa. What you're actually buying is a phenotype someone selected from a popular cross, grown by someone you may or may not trust. Pick by grower, not by name.

Overview

Mimosa is a hybrid cannabis cultivar bred by Symbiotic Genetics, who released it in the late 2010s and won a High Times Cannabis Cup category with it in 2018 [1]. The strain became commercially significant for two reasons: it tasted convincingly of orange and stone fruit at a time when 'gas' and 'cookies' flavors dominated shelves, and it tested high in THC without the harsh terpene profile of OG-descended lines.

The name comes from the brunch cocktail, not the tree. The most circulated cut is sometimes called 'Mimosa #26,' which Symbiotic selected and propagated; many commercial 'Mimosa' products sold today trace to that phenotype or to seed-grown approximations of it Weak / limited.

Chemistry

Cannabinoids. Mimosa is a THC-dominant Type I chemotype. Dispensary lab results commonly land in the 19–27% total THC range, with CBD under 0.5%. There is no published peer-reviewed chemotyping of Mimosa specifically — these figures come from aggregated dispensary COAs and should be treated as ballpark, not specification Weak / limited.

Terpenes. Reported dominant terpenes vary by grower and pheno. Limonene is the most frequently reported lead terpene, consistent with the citrus aroma, often with caryophyllene and myrcene as secondaries Weak / limited. Some phenos lean terpinolene-dominant, which shifts the aroma toward pine and tropical notes. Total terpene content in well-grown samples is typically 1.5–2.5%.

A caution: terpene percentages on labels are notoriously variable between labs and between harvests of the same cut [2]. Don't treat a single COA as the strain's 'profile.'

Reported effects

There is no clinical research on Mimosa. Anything anyone tells you about its effects is either (a) their personal experience, (b) crowd-sourced averages from sites like Leafly, or (c) marketing copy [evidence:none for strain-specific claims].

With that caveat: users commonly describe Mimosa as alert and talkative rather than sedating, which is plausible given its limonene-forward, low-myrcene tendency and high THC Anecdote. Claims that it treats anxiety, depression, fatigue, or ADHD are folklore — the underlying compounds (THC, limonene) have some preclinical and limited human data on mood and anxiety, but those data do not transfer to specific strain recommendations [3][4].

The 'indica vs sativa predicts effects' framework that gets applied to Mimosa ('it's a sativa hybrid so it's daytime') is not supported by chemical analysis of commercial cannabis [5]. Two Mimosa samples from different growers can produce different experiences.

Lineage

Symbiotic Genetics states Mimosa is Clementine x Purple Punch [1]. Clementine is a Crockett Family Farms cut (Tangie x Lemon Skunk) responsible for much of the citrus character; Purple Punch (Larry OG x Granddaddy Purple) contributes the dense bud structure and occasional purple expression.

This lineage is broadly accepted, but a few things are worth flagging:

No public genomic data (e.g. Phylos or Medicinal Genomics submissions) definitively confirms or refutes the stated parents Disputed.

Cultivation basics

Mimosa is considered intermediate to grow. Reported characteristics from breeders and grower forums Anecdote:

Mimosa seeds are sold by Symbiotic Genetics and several authorized partners; many 'Mimosa' seeds on the gray market are F2s or unrelated crosses using the name.

Marketing vs. reality

Marketing says: 'Energizing sativa, perfect for mornings, fights fatigue and depression, uplifting cerebral high.'

Reality: Mimosa is a high-THC hybrid that tastes like citrus. Whether it 'energizes' you depends on your tolerance, dose, the specific pheno, how it was grown and cured, and your neurochemistry. The 'morning strain' framing is brand language, not pharmacology.

Marketing says: 'Mimosa has X% limonene, the energizing terpene.'

Reality: Limonene percentages vary widely between samples. The idea that any single terpene reliably produces a specific mood effect at the doses found in inhaled cannabis is not well supported in humans [6] Weak / limited. The 'entourage effect' is a plausible hypothesis, not a proven mechanism for predicting strain-level outcomes.

Bottom line: If you like the way Mimosa tastes and a specific grower's version works for you, that's a perfectly good reason to buy it. Just don't expect the name on the jar to guarantee the experience.

Sources

  1. Reported High Times Staff. (2018). 'The 2018 High Times SoCal Cannabis Cup: Medical Winners.' High Times.
  2. Peer-reviewed Smith, C. J., Vergara, D., Keegan, B., & Jikomes, N. (2022). 'The phytochemical diversity of commercial cannabis in the United States.' PLOS ONE, 17(5), e0267498.
  3. Peer-reviewed Stith, S. S., Li, X., Diviant, J. P., et al. (2020). 'The effectiveness of common cannabis products for treatment of anxiety.' Journal of Affective Disorders, 273, 121–129.
  4. Peer-reviewed Komori, T., Fujiwara, R., Tanida, M., et al. (1995). 'Effects of citrus fragrance on immune function and depressive states.' Neuroimmunomodulation, 2(3), 174–180.
  5. Peer-reviewed Watts, S., McElroy, M., Migicovsky, Z., Maassen, H., van Velzen, R., & Myles, S. (2021). 'Cannabis labelling is associated with genetic variation in terpene synthase genes.' Nature Plants, 7, 1330–1334.
  6. Peer-reviewed Russo, E. B. (2011). 'Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.' British Journal of Pharmacology, 163(7), 1344–1364.

How this page was made

Generation history

Apr 6, 2026
Fact-check pass — raised 4 flags
Apr 5, 2026
Initial draft

Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.